Rothschild & Co Asset Management US’s Protagonist Therapeutics PTGX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.67M	Sell	153,294 -1,188	-0.8%	-$10K	0.03%	229
2022 Q3	$1.3M	Sell	154,482 -212,635	-58%	-$2.01M	0.02%	239
2022 Q2	$2.9M	Sell	367,117 -12,009	-3%	-$145K	0.04%	224
2022 Q1	$8.98M	Sell	379,126 -111,898	-23%	-$3.15M	0.11%	148
2021 Q4	$16.8M	Buy	491,024 +273,541	+126%	+$8.65M	0.2%	126
2021 Q3	$3.85M	Sell	217,483 -170,745	-44%	-$7.28M	0.05%	228
2021 Q2	$17.4M	Sell	388,228 -46,021	-11%	-$1.52M	0.21%	138
2021 Q1	$11.2M	Buy	+434,249	New	+$11M	0.14%	184

Other funds holding PTGX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rothschild & Co Asset Management US's PTGX Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Protagonist Therapeutics (PTGX) stake by 0.77% in Q4 2022, selling an estimated $10K and leaving 153,294 shares worth $1.67M. The position accounts for 0.03% of the portfolio, ranked #229.

Rothschild & Co Asset Management US first reported a position in PTGX in Q1 2021 and has held it in 8 quarters since. The position peaked at $17.4M in Q2 2021. 137 funds tracked by Wall St. Rank hold PTGX as of Q4 2022.

Rothschild & Co Asset Management US held 153,294 shares of Protagonist Therapeutics worth $1.67M as of Q4 2022.
Rothschild & Co Asset Management US sold 1,188 Protagonist Therapeutics shares in Q4 2022, an estimated $10K.
Protagonist Therapeutics made up 0.03% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #229 holding.
Rothschild & Co Asset Management US first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 8 quarters since.
Rothschild & Co Asset Management US's Protagonist Therapeutics position peaked at $17.4M in Q2 2021.
137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.